Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
By blocking IL 4 and IL 13 signaling, Dupixent reduces type 2 inflammation to shrink nasal polyps and restore olfactory nerve function, enabling rapid smell recovery in most CRSwNP patients with sustained benefits through one year.
Important details on who may benefit, administration schedule, cost, insurance requirements, safety monitoring and realistic timelines for improvement are outlined below. See below for a complete picture before deciding on your next steps.
Loss of smell (anosmia) is one of the most distressing symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). For many patients, no amount of nasal sprays, steroids or even surgery fully restores their ability to smell. That's where Dupixent® (dupilumab) comes in. But can Dupixent bring back sense of smell nasal polyps really? Let's explore the science behind true remission, what the clinical trials show, and what you should consider before starting therapy.
Dupixent is a monoclonal antibody that specifically blocks IL-4 and IL-13 signaling. By doing so, it:
Rather than temporarily shrinking polyps like steroids, Dupixent disrupts the underlying immune cascade, offering the potential for sustained, true remission.
Two pivotal studies—SINUS-24 and SINUS-52—evaluated Dupixent in adults with CRSwNP already on standard therapy.
70% of patients reported clinically meaningful smell recovery by Week 52
These data show that blocking IL-4/IL-13 not only shrinks polyps but allows repair of the olfactory system.
Many treatments offer short-lived symptom control:
Dupixent's approach:
Consider a Dupixent consultation if you have:
If you're experiencing nasal polyp symptoms or loss of smell and want to understand your condition better before your doctor visit, use this free Medically approved LLM Symptom Checker Chat Bot to explore your symptoms and get personalized health insights.
Dupixent is generally well tolerated, but it's important to discuss potential side effects and monitoring with your doctor:
Common (≥2% of patients)
Less common
Monitoring may include periodic blood tests and eye exams. Always report new or worsening symptoms to your healthcare provider.
Before starting Dupixent:
While individual experiences vary, here are some common themes from patients who have regained their sense of smell:
These anecdotes mirror the clinical trial data, reinforcing the potential for life-changing benefits.
Dupixent represents a breakthrough in targeting the underlying causes of CRSwNP and anosmia. If you're struggling with nasal polyps and loss of smell:
Always speak to a healthcare professional about any treatment changes. If you experience severe symptoms—such as sudden, complete loss of smell, high fever, severe facial pain, or vision changes—seek medical attention promptly, as these may signal complications requiring urgent care.
Dupixent offers hope for genuine, lasting remission of nasal polyp symptoms and a return of the sense of smell. While not a cure, its targeted mechanism addresses the immune dysfunction at the heart of the disease. Speak to your doctor today to see if Dupixent could help you breathe easier, smell better, and reclaim your quality of life.
(References)
* Geng C, Zhang W, Cui H, et al. Effect of Dupilumab on Olfactory Function in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2022 Jul;167(1):50-58.
* Tan BK, Evans T, Peters AT, et al. Sustained Improvement in Olfaction After Dupilumab Treatment for Chronic Rhinosinusitis With Nasal Polyps. Am J Rhinol Allergy. 2021 Jan;35(1):103-110.
* Bachert C, Han JK, Lange B, et al. Improvement of Olfactory Function in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1218-1226.e2.
* Stevens WW, Tan BK, Tan JS, et al. Dupilumab Improves Objective Olfactory Function in Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2775-2777.e1.
* Bachert C, Hellings PW, Mullol J, et al. Long-term efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps: an open-label extension study. Lancet Respir Med. 2020 Sep;8(9):890-900.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.